INMUNE BIO INC (INMB) Stock Price, Quote, News and Overview
NASDAQ:INMB - Nasdaq - US45782T1051 - Common Stock - Currency: USD
INMB Quote, Performance and Key Statistics
7.7
-0.22 (-2.78%)
The current stock price of INMB is 7.7 USD. In the past month the price increased by 5.62%. In the past year, price decreased by -9.31%.
INMB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.9 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About INMB
Company Profile
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 22 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Company Info
INMUNE BIO INC
225 Ne Mizner Blvd, Suite 640
Boca Raton FLORIDA 92037 US
CEO: Raymond J. Tesi
Employees: 18
Phone: 18589643720
INMUNE BIO INC / INMB FAQ
What is the stock price of INMUNE BIO INC today?
The current stock price of INMB is 7.7 USD. The price decreased by -2.78% in the last trading session.
What is the ticker symbol for INMUNE BIO INC stock?
The exchange symbol of INMUNE BIO INC is INMB and it is listed on the Nasdaq exchange.
On which exchange is INMB stock listed?
INMB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INMUNE BIO INC stock?
11 analysts have analysed INMB and the average price target is 23.87 USD. This implies a price increase of 209.97% is expected in the next year compared to the current price of 7.7. Check the INMUNE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INMUNE BIO INC worth?
INMUNE BIO INC (INMB) has a market capitalization of 178.72M USD. This makes INMB a Micro Cap stock.
How many employees does INMUNE BIO INC have?
INMUNE BIO INC (INMB) currently has 18 employees.
What are the support and resistance levels for INMUNE BIO INC (INMB) stock?
INMUNE BIO INC (INMB) has a support level at 7.63 and a resistance level at 7.87. Check the full technical report for a detailed analysis of INMB support and resistance levels.
Is INMUNE BIO INC (INMB) expected to grow?
The Revenue of INMUNE BIO INC (INMB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the INMB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INMUNE BIO INC (INMB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INMB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INMB, evaluating the profitability, health, valuation and growth aspects
- INMUNE BIO INC (INMB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INMUNE BIO INC (INMB) Sales and EPS estimates to see what analysts future expectations are.
- INMUNE BIO INC (INMB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INMUNE BIO INC (INMB) Insider and Institutional Ownership to learn about the owners and their transactions.
- INMUNE BIO INC (INMB) Stock Chart to make your own analysis
- INMUNE BIO INC (INMB) Latest news and press-releases to stay up to date.
Does INMUNE BIO INC (INMB) stock pay dividends?
INMB does not pay a dividend.
When does INMUNE BIO INC (INMB) report earnings?
INMUNE BIO INC (INMB) will report earnings on 2025-07-30.
What is the Price/Earnings (PE) ratio of INMUNE BIO INC (INMB)?
INMUNE BIO INC (INMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.93).
What is the Short Interest ratio of INMUNE BIO INC (INMB) stock?
The outstanding short interest for INMUNE BIO INC (INMB) is 35.3% of its float. Check the ownership tab for more information on the INMB short interest.
INMB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to INMB. When comparing the yearly performance of all stocks, INMB is a bad performer in the overall market: 72.44% of all stocks are doing better.
INMB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INMB. No worries on liquidiy or solvency for INMB as it has an excellent financial health rating, but there are worries on the profitability.
INMB Financial Highlights
Over the last trailing twelve months INMB reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS decreased by -0.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -107.92% | ||
| ROE | -137.49% | ||
| Debt/Equity | 0 |
INMB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to INMB. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 15.69% and a revenue growth -100% for INMB